SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($3.25), $0.36 better than the analyst estimate of ($3.61). Revenue for the quarter came in at $1.96 million versus the consensus estimate of $3.68 million.

“The progress we made in 2019 across our depression, neuropsych and neurology franchises supports our vision to make medicines that matter,” said Jeff Jonas, chief executive officer of Sage Therapeutics. “Our focus in 2020 will be guided by perseverance, disciplined execution and rigorous prioritization designed to achieve an optimal pace of innovation for what we believe is a leading, novel portfolio of NCEs dedicated to treating brain health disorders. Our most immediate goal is to find the most efficient pathway to bring new treatments to patients as quickly as possible.”

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.